SCHEMBL657703

SCHEMBL657703

COc1ccc2nc(C)c(-c3ccnc(C4(c5ccc(C(=O)NO)cc5)CC4)n3)n2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
HDAC6 Q9UBN7 6/20 0.37
HDAC2 Q92769 4/20 0.37
KDM1A O60341 3/20 0.37
HDAC3 O15379 2/20 0.37
MAP3K14 Q99558 2/20 0.37
AKT1 P31749 3/20 0.36
AKT2 P31751 3/20 0.36
PIK3CD O00329 1/20 0.36
PIK3R1 P27986 1/20 0.36
MCHR1 Q99705 1/20 0.35
HDAC8 Q9BY41 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
CDK4 P11802 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL655707 0.92 HDAC1 (0.39) HDAC1MAP3K14AKT1AKT2PIK3CD
SCHEMBL655847 0.89 HDAC1 (0.49) HDAC1HDAC6HDAC2HDAC3MAP3K14
SCHEMBL3358836 0.88 MAP3K14 (0.50) HDAC1HDAC6HDAC2HDAC3MAP3K14
SCHEMBL658869 0.87 HDAC1 (0.36) HDAC1HDAC6HDAC2KDM1AHDAC3
SCHEMBL657662 0.87 HDAC1 (0.55) HDAC1HDAC6HDAC2HDAC3HDAC8
SCHEMBL658247 0.86 HDAC1 (0.39) HDAC1HDAC6HDAC2HDAC3MAP3K14
SCHEMBL658761 0.86 AKT1 (0.47) HDAC1MAP3K14AKT1AKT2KDM4E
SCHEMBL3348358 0.84 CDK2 (0.52) HDAC1CDK4CCNE1CDK2KDM4E
SCHEMBL657216 0.84 CDK2 (0.37) HDAC1HDAC6HDAC2HDAC3MAP3K14
SCHEMBL3352693 0.83 CA1 (0.38) HDAC1CA1CA2HDAC6HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885CA1 2427/4885CA2 2220/4885
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885CA1 2427/4885CA2 2220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.